INDP - Indaptus Therapeutics to Present Positive Data on Lead Product Candidate Decoy20 at STING & TLR-Targeted Therapies Summit | Benzinga
- Chief Scientific Officer Dr. Newman to present initial clinical data that further validates Company's "Pulse-Prime" hypothesis
- Dr. Newman also named Chair of the Summit
NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its founder and Chief Scientific Officer, Michael Newman, Ph.D., will present additional data on the Company's lead product candidate, Decoy20, at the 5th Annual STING & TLR-Targeted Therapies Summit in San Diego on June 19-20, 2024. Dr. Newman has also been named chair of the Summit.
Dr. Newman's presentation, titled, "Hitting Multiple Immune System Targets with a Passively Targeted, Pulsed, Systemic Approach to Amplify Efficacy & Widen the Therapeutic Index," will be presented at 9:15 a.m. on June 20th. It will highlight how the Company's pre-clinical data and, in particular, its "Pulse-Prime" hypothesis, are being further validated by its initial Decoy20 clinical data.
Jeffrey Meckler, Indaptus CEO commented, "This is the second year in a row that Dr. Newman has been named chair of the STING & TLR conference. This well-deserved recognition reflects both Michael's expertise in immuno-oncology, and the Company's solid progress developing a novel treatment using engineered killed bacteria to broadly stimulate the immune system in patients with advanced solid tumors. Further, we are grateful for the opportunity to share our latest progress on Decoy20 with the scientific community. The 5th Annual STING & TLR-Targeted Therapies Summit provides an excellent forum for companies to present their latest research on Toll-Like Receptor-based therapies."
About the 5th Annual STING & TLR-Targeted Therapies Summit
The hansonwade STING & TLR Targeted Therapies Summit returns as the only industry-led event converging those with crucial insights to fuel the long-awaited success of innate immunity targeted therapies. With the field venturing into new approaches to strike that balance between safety and efficacy, from immune agonist conjugates to combination approaches and novel dosing methods, stay ahead of this evolving field with the latest insights to steer you towards success in the clinic. The therapeutic potential of harnessing the innate immune system has been waiting to be untapped for a while. Hear from the leading minds in immune-oncology and join the dedicated community to breakthrough barriers to success within your innate immunotherapy pipeline.
For more information, please visit: https://sting-tlr-targeting-therapies.com/
About Indaptus Therapeutics
Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company's novel approach is based on the hypothesis that efficient ...